The U.S. FDA is considering lifting bans on over a dozen injectable peptides previously prohibited due to safety risks, following advocacy by Health and Human Services Secretary Robert F. Kennedy Jr. This shift could impact developers working in peptide therapies, potentially opening new avenues for research and treatment but also raising concerns about oversight and efficacy. Meanwhile, scientists developing custom gene editing treatments face FDA-imposed manufacturing hurdles that may limit academic efforts and favor industrial-scale production.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



